Biosimilars
Our bisiomilars product portfolio
Product
Potential
Indications
Preclinical
Cell line
Preclinical
Process dev.
Preclinical
GMP batch
Phase 1
Phase 2
Phase 3
BTPH-032
Adalimumab (Humira)
AIID
BTPH-023
Denozumab (Prolia)
Osteoporosis
BTPH-070
Cetuximab (Erbitux)
Oncology
BTPH-091
Cetolizumab pegol (Cimzia)
AIID
CT-1902
Aflibercept (Eylea)
Ophthalmology
CT-1901
Bevacizumab (Avastin)
Oncology
CT-1903
Trastuzumab (Herceptin)
Oncology
BTPH-061
Insulin (E. coli)
Diabetes
BTPH-021
BTPH-095
Insulin glargine (E. coli)
Diabetes
BTPH-0051
BTPH-027
IFNα2b interferon
Virology,
oncology
BTPH-024
GCSF (Granulocyte colony- stimulating factor) (E.coli)
Oncology
CT 2002
GM-CSF (E. coli)
Oncology
CT 2001
HGH (Human growth hormone) (E. coli)
Hormone
BTPH-009
Factor VII
Hematology
BTPH-0061
BTPH-026
α-1-antitrypsin
Pulmonology
BTPH-011
IFNα2b-IFNα2b (Interferon alpha-2b - Interferon alpha-2b)
Oncology